Alkem Laboratories Sees Major Stake Transactions Amid New Product Launch
Alkem Labs shares in focus as Goldman, Morgan Stanley, others purchase stake in Rs 930-crore block deal
The Economic TimesImage: The Economic Times
Alkem Laboratories experienced significant trading activity with block deals worth approximately ₹930 crore, involving major institutional buyers like ICICI Prudential and Goldman Sachs. The company also launched semaglutide pre-filled syringes for diabetes treatment in India, marking a notable expansion in its product offerings.
- 01Alkem Labs shares traded in block deals totaling ₹930 crore at ₹5,200 per share.
- 02ICICI Prudential Mutual Fund purchased the largest stake, acquiring 9.04 lakh shares.
- 03The company launched semaglutide pre-filled syringes in India at ₹350, becoming the first to do so.
- 04Alkem reported a 40.7% increase in pre-exceptional profit to ₹557.8 crore for Q4FY26.
- 05Despite a decline in net profit due to one-time charges, Alkem's revenue grew 14.6% year-on-year.
Advertisement
In-Article Ad
Alkem Laboratories is under the spotlight following substantial block transactions worth approximately ₹930 crore, with 17.88 lakh shares traded at ₹5,200 each on the National Stock Exchange. Notable buyers included ICICI Prudential Mutual Fund, which acquired 9.04 lakh shares, and HDFC Mutual Fund, with 5.1 lakh shares. The selling entities included Jayanti Sinha and the Samprada & Nanhamati Singh Family Trust. Additionally, Alkem launched semaglutide pre-filled syringes in India for diabetes management, priced at ₹350, marking a significant addition to its product line. In its Q4FY26 results, Alkem reported a 40.7% year-on-year increase in pre-exceptional profit, reaching ₹557.8 crore, driven by strong growth in both domestic and international markets. Domestic sales rose by 8.8% to ₹2,324.5 crore, while international revenue increased by 25.4% to ₹1,222 crore. However, net profit after exceptional items fell by 22.7% to ₹236.5 crore due to one-time charges of around ₹135 crore.
Advertisement
In-Article Ad
The trading activity reflects strong institutional interest in Alkem, indicating potential stability in the healthcare sector amidst market volatility.
Advertisement
In-Article Ad
Reader Poll
What do you think about the recent stake purchases in Alkem Laboratories?
Connecting to poll...
More about Alkem Laboratories

Alkem Laboratories Introduces Semaglutide Pre-Filled Syringes in India at ₹350
Business Standard • Jun 3, 2026
Alkem Laboratories Promoters Divest 1.5% Stake for ₹930 Crore
The Economic Times • Jun 2, 2026
Alkem Laboratories enfrenta desafíos a pesar de un crecimiento sólido en el sector farmacéutico
Marketscreenerc • Jun 2, 2026
Read the original article
Visit the source for the complete story.


&w=1200&q=75)
